...
首页> 外文期刊>Inflammatory bowel diseases >Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease.
【24h】

Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease.

机译:次黄嘌呤鸟嘌呤磷酸核糖基转移酶活性与6-硫鸟嘌呤核苷酸浓度和硫嘌呤诱导的白细胞减少症在炎性肠病的治疗中有关。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Thiopurine drugs are widely used in the treatment of inflammatory bowel disease (IBD). The polymorphic enzyme thiopurine S-methyltransferase (TPMT) is of importance for thiopurine metabolism and adverse events occurrence. The role of other thiopurine-metabolizing enzymes is less well known. This study investigated the effects of TPMT and hypoxanthine guanine phosphoribosyltransferase (HPRT) activities on 6-thioguanine nucleotides (6-TGNs) concentrations and thiopurine-induced leukopenia in patients with IBD. METHODS: Clinical data and blood samples were collected from 120 IBD patients who were receiving azathioprine (AZA)/6-mercaptopurine (6-MP) therapy. Erythrocyte TPMT, HPRT activities and 6-TGNs concentrations were determined. HPRT activity and its correlation with TPMT activity, 6-TGNs level, and leukopenia were evaluated. RESULTS: The HPRT activity of all patients ranged from 1.63-3.33 (2.31 +/- 0.36) mumol/min per g Hb. HPRT activity was significantly higher in patients with leukopenia (27, 22.5%) than without (P < 0.001). A positive correlation between HPRT activity and 6-TGNs concentration was found in patients with leukopenia (r = 0.526, P = 0.005). Patients with HPRT activity > 2.70 mumol/min per g Hb could have an increased risk of developing leukopenia (odds ratio = 7.47, P < 0.001). No correlation was observed between TPMT activity and HPRT activity, 6-TGNs concentration, or leukopenia. CONCLUSIONS: High levels of HPRT activity could be a predictor of leukopenia and unsafe 6-TGN concentrations in patients undergoing AZA/6-MP therapy. This could partly explain the therapeutic response or toxicity that could not be adequately explained by the polymorphisms of TPMT.
机译:背景:硫嘌呤药物被广泛用于治疗炎症性肠病(IBD)。多态性酶硫嘌呤S-甲基转移酶(TPMT)对于硫嘌呤代谢和不良事件的发生很重要。其他硫代嘌呤代谢酶的作用尚不为人所知。这项研究调查了TPMT和次黄嘌呤鸟嘌呤磷酸核糖基转移酶(HPRT)活性对IBD患者6-硫鸟嘌呤核苷酸(6-TGNs)浓度和硫嘌呤诱导的白细胞减少症的影响。方法:从120名接受硫唑嘌呤(AZA)/ 6-巯基嘌呤(6-MP)治疗的IBD患者中收集临床数据和血液样本。测定了红细胞的TPMT,HPRT活性和6-TGNs浓度。评估了HPRT活性及其与TPMT活性,6-TGNs水平和白细胞减少的相关性。结果:所有患者的HPRT活性范围为每g Hb 1.63-3.33(2.31 +/- 0.36)mumol / min。白细胞减少症患者的HPRT活性显着高于无白细胞减少症的患者(27,22.5%)(P <0.001)。白细胞减少症患者的HPRT活性与6-TGNs浓度呈正相关(r = 0.526,P = 0.005)。 HPRT活性> 2.70 mumol / min / g Hb的患者发生白细胞减少症的风险可能会增加(优势比= 7.47,P <0.001)。在TPMT活性和HPRT活性,6-TGNs浓度或白细胞减少之间未发现相关性。结论:高水平的HPRT活性可能是接受AZA / 6-MP治疗的患者白细胞减少和不安全的6-TGN浓度的预测指标。这可以部分解释不能由TPMT多态性充分解释的治疗反应或毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号